Girish S. Kulkarni

Research interests

Publications

• Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial

  Nature Medicine · 2025 · 10.1038/s41591-025-03738-z

• Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial

  The Lancet Oncology · 2024 · 10.1016/s1470-2045(24)00178-5

• Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis

  The Lancet Oncology · 2023 · https://doi.org/10.1016/s1470-2045(23)00170-5

• Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma: AUA/SUO Guideline

  The Journal of Urology · 2023 · 10.1097/ju.0000000000003480

• APPRAISE-AI Tool for Quantitative Evaluation of AI Studies for Clinical Decision Support

  JAMA Network Open · 2023 · 10.1001/jamanetworkopen.2023.35377

• Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00147-9

• Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials

  Annals of Oncology · 2020 · 10.1016/j.annonc.2019.10.008

• Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG).

  Journal of Clinical Oncology · 2019 · 10.1200/jco.2019.37.7_suppl.350

• Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations

  European Urology · 2018 · 10.1016/j.eururo.2018.06.024

• Metastatic renal cell carcinoma: Patterns and predictors of metastases—A contemporary population-based series

  Urologic Oncology Seminars and Original Investigations · 2017 · 10.1016/j.urolonc.2017.06.060

• Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic

  Journal of Clinical Oncology · 2017 · https://doi.org/10.1200/jco.2016.69.2327

• Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis

  European Urology · 2017 · 10.1016/j.eururo.2017.10.002

• Outcomes among patients discharged from the emergency department with a diagnosis of peripheral vertigo

  Annals of Neurology · 2015 · 10.1002/ana.24521

• Dissecting the Association Between Metabolic Syndrome and Prostate Cancer Risk: Analysis of a Large Clinical Cohort

  European Urology · 2014 · 10.1016/j.eururo.2014.01.040

• Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study

  The Lancet Oncology · 2014 · 10.1016/s1470-2045(13)70606-5

• Pre-treatment neutrophil-to-lymphocyte ratio as predictor of adverse outcomes in patients undergoing radical cystectomy for urothelial carcinoma of the bladder

  British Journal of Cancer · 2014 · 10.1038/bjc.2014.305

• Impact of the U.S. Preventive Services Task Force Recommendations against Prostate Specific Antigen Screening on Prostate Biopsy and Cancer Detection Rates

  The Journal of Urology · 2014 · 10.1016/j.juro.2014.11.096

• Metformin Use and All-Cause and Prostate Cancer–Specific Mortality Among Men With Diabetes

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2012.46.7043

• Immediate Post–Transurethral Resection of Bladder Tumor Intravesical Chemotherapy Prevents Non–Muscle-invasive Bladder Cancer Recurrences: An Updated Meta-analysis on 2548 Patients and Quality-of-Evidence Review

  European Urology · 2013 · 10.1016/j.eururo.2013.06.009

• Higher surgeon and hospital volume improves long‐term survival after radical cystectomy

  Cancer · 2013 · 10.1002/cncr.28235

• Longer Wait Times Increase Overall Mortality in Patients With Bladder Cancer

  The Journal of Urology · 2009 · 10.1016/j.juro.2009.06.041

• An Updated Critical Analysis of the Treatment Strategy for Newly Diagnosed High-grade T1 (Previously T1G3) Bladder Cancer

  European Urology · 2009 · https://doi.org/10.1016/j.eururo.2009.08.024

• Clinical predictors of gleason score upgrading

  Cancer · 2007 · 10.1002/cncr.22712

• Optimal Management of High-Risk T1G3 Bladder Cancer: A Decision Analysis

  PLoS Medicine · 2007 · 10.1371/journal.pmed.0040284

• Evidence for a Biopsy Derived Grade Artifact Among Larger Prostate Glands

  The Journal of Urology · 2006 · 10.1016/s0022-5347(05)00236-3

Current projects

No projects listed.